(HLN) Haleon - Overview
Stock: Toothpaste, Vitamins, Cold-Remedy, Pain-Reliever, Antacid
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.76% |
| Yield on Cost 5y | 2.46% |
| Yield CAGR 5y | 30.09% |
| Payout Consistency | 100.0% |
| Payout Ratio | 52.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.3% |
| Relative Tail Risk | 0.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 9.87 |
| Character TTM | |
|---|---|
| Beta | 0.186 |
| Beta Downside | -0.040 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.11% |
| CAGR/Max DD | 0.56 |
Description: HLN Haleon January 28, 2026
Haleon plc (NYSE: HLN) is a global consumer-health company that designs, manufactures, and sells a portfolio of over-the-counter (OTC) products across six regions. Its brands span oral care (Sensodyne, Aquafresh), vitamins and supplements (Centrum, Emergen-C), respiratory relief (Theraflu, Flonase), pain and inflammation (Advil, Voltaren), and digestive health (TUMS, ENO). The firm originated as DRVW 2022 plc and rebranded to Haleon in February 2022; its corporate roots trace back to 1715, with headquarters in Weybridge, United Kingdom.
Key recent metrics (FY 2024): revenue $13.8 billion, up 4.2 % YoY, driven by a 7 % increase in North-American OTC sales and a 5 % rise in emerging-market vitamin demand; adjusted EBITDA margin held at 18.5 % despite inflationary input costs; dividend yield 3.2 % and payout ratio 70 %. Sector-wide, the global consumer-health market is projected to grow 5 % CAGR through 2028, bolstered by aging demographics and higher discretionary spend on self-care products. A notable macro driver is the U.S. consumer confidence index, which has remained above 100 in Q4 2025, supporting continued demand for premium OTC brands.
For a deeper, data-driven view of Haleon’s valuation and risk profile, you may find ValueRay’s analytical toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 2.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: -3.75% < 20% (prev -5.38%; Δ 1.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 3.94b > Net Income 2.41b |
| Net Debt (7.78b) to EBITDA (4.04b): 1.93 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.53b) vs 12m ago -1.61% < -2% |
| Gross Margin: 63.19% > 18% (prev 0.61%; Δ 6258 % > 0.5%) |
| Asset Turnover: 50.71% > 50% (prev 50.83%; Δ -0.11% > 0%) |
| Interest Coverage Ratio: 7.63 > 6 (EBITDA TTM 4.04b / Interest Expense TTM 484.5m) |
Altman Z'' 4.48
| A: -0.02 (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| B: 0.86 (Retained Earnings 27.27b / Total Assets 31.83b) |
| C: 0.11 (EBIT TTM 3.70b / Avg Total Assets 32.61b) |
| D: 1.01 (Book Value of Equity 15.94b / Total Liabilities 15.83b) |
| Altman-Z'' Score: 4.48 = AA |
Beneish M -3.09
| DSRI: 1.03 (Receivables 2.14b/2.14b, Revenue 16.54b/16.98b) |
| GMI: 0.97 (GM 63.19% / 61.18%) |
| AQI: 1.01 (AQ_t 0.81 / AQ_t-1 0.80) |
| SGI: 0.97 (Revenue 16.54b / 16.98b) |
| TATA: -0.05 (NI 2.41b - CFO 3.94b) / TA 31.83b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of HLN shares?
Over the past week, the price has changed by +4.87%, over one month by +6.91%, over three months by +16.68% and over the past year by +17.58%.
Is HLN a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.8 | 7.7% |
| Analysts Target Price | 11.8 | 7.7% |
| ValueRay Target Price | 11.8 | 7.7% |
HLN Fundamental Data Overview February 03, 2026
P/E Trailing = 22.2766
P/E Forward = 18.622
P/S = 4.2312
P/B = 2.0815
P/EG = 2.9106
Revenue TTM = 16.54b GBP
EBIT TTM = 3.70b GBP
EBITDA TTM = 4.04b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 41.94b GBP (34.16b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 7.63 (Ebit TTM 3.70b / Interest Expense TTM 484.5m)
EV/FCF = 27.98x (Enterprise Value 41.94b / FCF TTM 1.50b)
FCF Yield = 3.57% (FCF TTM 1.50b / Enterprise Value 41.94b)
FCF Margin = 9.06% (FCF TTM 1.50b / Revenue TTM 16.54b)
Net Margin = 14.57% (Net Income TTM 2.41b / Revenue TTM 16.54b)
Gross Margin = 63.19% ((Revenue TTM 16.54b - Cost of Revenue TTM 6.09b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.32 (Enterprise Value 41.94b / Total Assets 31.83b)
Interest Expense / Debt = 1.53% (Interest Expense 129.0m / Debt 8.45b)
Taxrate = 24.37% (262.0m / 1.07b)
NOPAT = 2.80b (EBIT 3.70b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 1.93 (Net Debt 7.78b / EBITDA 4.04b)
Debt / FCF = 5.19 (Net Debt 7.78b / FCF TTM 1.50b)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.39% (Net Income 2.41b / Total Assets 31.83b)
RoE = 14.89% (Net Income TTM 2.41b / Total Stockholder Equity 16.19b)
RoCE = 15.56% (EBIT 3.70b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 11.09% (NOPAT 2.80b / Invested Capital 25.20b)
WACC = 5.52% (E(34.16b)/V(42.61b) * Re(6.60%) + D(8.45b)/V(42.61b) * Rd(1.53%) * (1-Tc(0.24)))
Discount Rate = 6.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.00%
[DCF Debug] Terminal Value 84.92% ; FCFF base≈1.60b ; Y1≈1.41b ; Y5≈1.15b
Fair Price DCF = 6.07 (EV 34.79b - Net Debt 7.78b = Equity 27.02b / Shares 4.45b; r=5.90% [WACC]; 5y FCF grow -15.03% → 2.90% )
EPS Correlation: 8.12 | EPS CAGR: 101.1% | SUE: -0.02 | # QB: 0
Revenue Correlation: 56.46 | Revenue CAGR: 23.41% | SUE: 1.66 | # QB: 1
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.011 | Revisions Net=+1 | Growth EPS=+10.1% | Growth Revenue=+4.3%